Evidence map›Paper›PMID 32454981›Full record

ArticleJournal of pharmaceutical policy and practice2020

Current regulatory approaches for accessing potential COVID-19 therapies.

Vesa Halimi, Armond Daci, Simona Stojanovska, Irina Panovska-Stavridis, Milena Stevanovic, Venko Filipce, Aleksandra Grozdanova

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmaceutical policy and practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. The use of remdesivir outside of clinical trials during the COVID-19 pandemic.Journal of pharmaceutical policy and practice · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Vesa Halimi1Faculty of Pharmacy, University Ss. Cyril and Methodius, Skopje, North Macedonia.
Armond Daci2Department of Pharmacy, Faculty of Medicine, University of Prishtina, Prishtina, Kosovo.
Simona Stojanovska3University Clinic of Hematology, Medical Faculty, University Ss. Cyril and Methodius, Skopje, North Macedonia.
Irina Panovska-Stavridis3University Clinic of Hematology, Medical Faculty, University Ss. Cyril and Methodius, Skopje, North Macedonia.
Milena Stevanovic4University Clinic of Infection diseases and febrile conditions, Medical Faculty, University Ss. Cyril and Methodius, Skopje, North Macedonia.
Venko Filipce5University Clinic for Neurosurgery, Medical Faculty, University Ss. Cyril and Methodius, Skopje, North Macedonia.
Aleksandra Grozdanova1Faculty of Pharmacy, University Ss. Cyril and Methodius, Skopje, North Macedonia.ORCID 0000-0002-0098-8691

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This commentary aims to elaborate challenges in the regulatory approaches for accessing and investigating COVID-19 potential therapies either with off-label use, compassionate use, emergency use or for clinical trials. Since no therapies have been formally approved and completely effective and safe to date, the best clinical choice is acquired only after consistent and fair communication and collaboration between licensed clinicians, researchers, regulatory authorities, manufacturers and patients.

Indexed as

Clinical practiceClinical studiesCompassionate useCOVID-19EMAEmergency useFDAOff-label useRegulatory

Identifiers

PMID32454981
PMCPMC7229878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.